title: Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting.
abstract: OBJECTIVE
  To describe healthcare resource use patterns and estimate healthcare costs of newly diagnosed Type 2 diabetes mellitus (T2DM) patients in Sweden.
  
  
  METHODS
  Patients with a newly diagnosed T2DM between 1999 and 2009 were identified from 84 Swedish primary care centres. Healthcare resource use data, excluding pharmaceuticals, were extracted from electronic patient records and a national patient register, and reported as per patient mean number of primary care contacts, laboratory tests and hospitalizations. Per patient mean healthcare costs are reported as annual and cumulative costs.
  
  
  RESULTS
  During a median (maximum) of 4.6 (9.0) years follow-up; 38,956 patients (183,513 patient years) on average made 81 primary care contacts, was hospitalized 2.14 times, and took 31 laboratory tests. Mean per patient annual healthcare costs were €4128 (95% CI, 4054-4199) the first year after diagnosis, €2708 (95% CI, 2641-2776) the second year, and €3030 (95% CI, 2854-3204) in year 9 (2012 values). Mean per patient cumulative healthcare costs were €26,503 (95% CI, 26,025-26,970) at 9 years of follow-up. Hospitalizations accounted for the majority of healthcare costs.
  
  
  CONCLUSIONS
  Although newly diagnosed T2DM patients require a substantial amount of healthcare services in primary care, hospitalizations account for the majority of healthcare costs.
authors: AstraZeneca Nordic-Baltic, Södertälje, Sweden. Electronic address: ugne.sabale@astrazeneca.com.
authors: Ugne
authors: U
authors: Sabale
authors: AstraZeneca Nordic-Baltic, Södertälje, Sweden.
authors: Johan
authors: J
authors: Bodegård
authors: Uppsala University, Uppsala, Sweden.
authors: Johan
authors: J
authors: Sundström
authors: Linköping University, Linköping, Sweden.
authors: Carl Johan
authors: CJ
authors: Östgren
authors: Lund University, Malmö, Sweden.
authors: Peter
authors: P
authors: Nilsson
authors: Uppsala University, Uppsala, Sweden.
authors: Gunnar
authors: G
authors: Johansson
authors: Uppsala University, Uppsala, Sweden.
authors: Bodil
authors: B
authors: Svennblad
authors: AstraZeneca Nordic-Baltic, Södertälje, Sweden.
authors: Martin
authors: M
authors: Henriksson
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000191:economics* / Q000628:therapy*; D003955:Diagnostic Tests, Routine / Q000191:economics; D057286:Electronic Health Records; D005260:Female; D005500:Follow-Up Studies; D017048:Health Care Costs / Q000639:trends; D006295:Health Resources / Q000191:economics* / Q000706:statistics & numerical data / Q000639:trends; D017721:Hospital Costs; D006792:House Calls / Q000191:economics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009819:Office Visits / Q000191:economics; D011320:Primary Health Care / Q000191:economics* / Q000706:statistics & numerical data / Q000639:trends; D012042:Registries; D012189:Retrospective Studies; D013548:Sweden; D013997:Time Factors; D016896:Treatment Outcome
keywords: Healthcare utilization, Healthcare costs, Retrospective observational study; Type 2 diabetes mellitus